NORTHWEST BIOTHERAPEUTICS, INC. LOAN AGREEMENT and PROMISSORY NOTE
Exhibit 4.5
| US $4 million | May 6, 2008 |
SECTION 1. GENERAL.
Al Rajhi Holdings WLL, a Bahrain company with offices at Al Moayyed Towers, Seef District, Manama
Bahrain, (“Al Rajhi” or the “Holder”) hereby grants to Northwest Biotherapeutics, Inc., a Delaware
corporation (the “Maker” or the “Company”) an unsecured bridge term loan facility of Four Million
Dollars (US$4.0 million) (the “Principal Amount”) subject to the terms of this Loan Agreement and
Promissory Note (this “Note”). The funding at closing of this Note will be US$4.0 million, and the
repayment on the Maturity Date will be US$4.24 million (the “Repayment Amount”). The Repayment
Amount minus the Principal Amount shall constitute original issue discount (“OID”). At the
Maturity Date, up to US$240,000 of the Repayment Amount may, at the election of the Holder in its
sole discretion, be paid in common stock of the Company on the terms set forth in this Note
(including, without limitation, the pricing set forth in Section 11 hereof). Al Rajhi shall
forthwith following execution of this Note advance the Principal Amount to the Company at the
account notified to Al Rajhi by the Company.
Following receipt of the Principal Amount and for value received, the Company hereby promises to
pay the Repayment Amount to the order of the Al Rajhi or its assigns, in accordance with this Note,
on October 30, 2008, or such earlier date as may be applicable under Sections 3 and 4 hereof (the
“Maturity Date”).
SECTION 2. PRE-PAYMENT.
This Note may be pre-paid in whole or in part prior to the Maturity Date, at the election of the
Maker. Any such pre-payment shall have no effect upon the Repayment Amount.
SECTION 3. DEFAULT PAYMENT.
Upon the occurrence of an Event of Default (as defined in Section 4 hereof) after notice as
provided in Section 17.1 hereof (“Event of Default”), default payments shall become due and payable
on any unpaid Repayment Amount that remains outstanding after the applicable Maturity Date (the
“Default Principal”). The default payments shall be assessed on a monthly basis at the beginning of
each month or partial month in which any Default Principal remains outstanding. Such default
payments shall be a fixed amount relating to such month or partial month, and shall not be pro
rated if the Default Principal is repaid by the Maker during such month. The amount of such
default payments shall be equal to the lowest of (i) 0.25% percent of the Default Principal per
month or partial month that such Default Principal remains outstanding, representing an annualized
rate of Default Payments of three percent (3%) per annum, or (ii) the maximum rate permitted under
applicable rules and regulations of the SBA, or (iii) the maximum
rate allowed by law (the “Default
Payments”). Such Default Payments shall commence upon the occurrence of an Event of Default and
continue until such Event of Default is fully cured or waived. The Default Payments shall be paid
in common stock of the Company, at a price per share as provided in Section 11 hereof.
SECTION 4. DEFAULTS.
4.1 Definitions. Each occurrence of any of the following events shall constitute an
“Event of Default”:
(a) if a default occurs in the payment of any Repayment Amount, or other amounts due under
this Note, whether at the due date thereof or upon acceleration thereof, and such default remains
uncured for ten (10) business days after written notice thereof from Holder;
(b) if any representation or warranty of Maker made herein shall have been false or misleading
in any material respect, or shall have contained any material omission, as of the date hereof;
(c) if a material default occurs in the due observance or performance on the part of Maker of
any covenant or agreement to be observed or performed pursuant to the terms of this Note and such
default remains uncured for ten (10) business days after written notice thereof from Holder;
(d) if Maker shall (i) discontinue its business, (ii) apply for or consent to the appointment
of a receiver, trustee, custodian or liquidator of Maker or any of its property, (iii) make a
general assignment for the benefit of creditors, or (iv) file a voluntary petition in bankruptcy,
or a petition or an answer seeking reorganization or an arrangement with creditors, or take
advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or
liquidation laws or statutes, or file an answer admitting the material allegations of a petition
filed against it in any proceeding under any such law;
(e) if there shall be filed against Maker an involuntary petition seeking reorganization of
Maker or the appointment of a receiver, trustee, custodian or liquidator of Maker or a substantial
part of its assets, or an involuntary petition under any bankruptcy, reorganization or insolvency
law of any jurisdiction, whether now or hereafter in effect (any of the foregoing petitions being
hereinafter referred to as an “Involuntary Petition”) and such Involuntary Petition shall not have
been dismissed within ninety (90) days after it was filed;
4.2
Remedies on Default.
(a) Upon each and every such Event of Default and at any time thereafter during the
continuance of such Event of Default: (i) any and all indebtedness and related amounts (including,
without limitation, Default Payments) due from Maker to Holder under this Note or otherwise shall
immediately become due and payable; and (ii) Holder may exercise all the rights of a creditor under
applicable law.
(b) In case any one or more Events of Default shall occur and be continuing, and acceleration
of this Note or any other indebtedness or obligation of Maker to Holder shall have occurred, Holder
may, inter alia, proceed to protect and enforce its rights by an action at law, suit in equity
and/or other appropriate proceeding, whether for the specific performance of any agreement
contained in this Note, or for an injunction against a violation of any of the terms hereof or
thereof or in furtherance of the exercise of any power granted hereby or thereby or by law. No
right conferred upon Holder by this Note shall be exclusive of any other right referred to herein
or therein or now or hereafter available at law, in equity, by statute or otherwise.
SECTION 5. DEFENSES.
5.1 No Offsets. The obligations of Maker under this Note shall not be subject to
reduction, limitation, impairment, termination, defense, set-off, counterclaim or recoupment for
any reason.
SECTION 6. FOLLOW-ON FINANCINGS.
Maker is seeking additional bridge financing, and longer term financing, to follow the bridge
loan facility provided by Al Rajhi under this Note. Maker and Holder anticipate that an additional
bridge loan facility of substantially the same amount as the Principal Amount hereunder, on
substantially the same terms and conditions as provided herein, may be provided by Toucan Capital
Fund II (“Toucan Capital”), or its affiliate Cognate BioServices, provided that regulatory waiver
and/or approval is obtained from the US Small Business Administration (“SBA”). It is anticipated
that the process of agency decision upon request for such waiver and/or approval may require
approximately thirty to forty five (30-45) days. Maker and Holder also anticipate that a longer
term financing, in a larger amount than the bridge loans, may be arranged by Maker prior to the
Maturity Date of this Note. Maker will use commercially reasonable efforts to obtain such longer
term financing, and to structure such financing to be non-dilutive to Company shareholders to the
extent commercially feasible.
SECTION 7. EXTENSION OF MATURITY.
7.1 Business Days. Should the Repayment Amount or any other amounts due under this
Note become due and payable on other than a business day, the due date thereof shall be extended to
the next succeeding business day. For the purposes of the preceding sentence, a business day shall
be any day that is not a Saturday or Sunday, or a legal holiday in England and Wales or in the
State of Delaware in the United States.
SECTION 8. ATTORNEYS’ FEES AND COLLECTION FEES.
In the event that all or part of the indebtedness evidenced by this Note is collected at law
or in equity, or in bankruptcy, receivership or other court proceedings, arbitration or mediation,
or any settlement of any of the foregoing, Maker agrees to pay, in addition to the Repayment Amount
and any other amounts due and payable hereunder, all costs of collection incurred by
Holder in
collecting or enforcing this Note, including, without limitation, reasonable attorneys’ fees and
expenses.
SECTION 9. WAIVERS, DISPUTES, JURISDICTION.
9.1
Waivers by Maker. Maker hereby waives presentment, demand for payment,
notice of dishonor, notice of protest and all other notices or demands in connection with the
delivery, acceptance, performance or default of this Note.
9.2
Actions of Holder not a Waiver. No delay by Holder in exercising any
power or right hereunder shall operate as a waiver of any power or right, nor shall any single or
partial exercise of any power or right preclude other or further exercise thereof, or the exercise
of any other power or right hereunder or otherwise; and no waiver or modification of the terms
hereof shall be valid unless set forth in writing by Holder and then only to the extent set forth
therein.
9.3 Dispute Resolution. Any dispute arising out of or in connection with this
Note, including any question regarding its existence, validity or termination, shall be referred to
and finally resolved by arbitration under the Rules of the London Court of International
Arbitration, which are deemed to be incorporated by reference into this Section. The number of
arbitrators shall be three, unless the parties jointly determine that the number of arbitrators
shall be one. The seat, or legal place, of arbitration shall be London, United Kingdom. The
language to be used in the arbitral proceedings shall be English.
9.4
Waiver of Jury Trial. MAKER WAIVES ANY RIGHTS IT MAY HAVE TO A JURY TRIAL
OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF THIS AGREEMENT OR ANY DEALINGS BETWEEN MAKER AND
HOLDER RELATING TO THE SUBJECT MATTER OF THIS NOTE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE
ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE
SUBJECT MATTER OF THIS NOTE, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, AND ALL
OTHER COMMON LAW AND STATUTORY CLAIMS. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE
MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS,
SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENT OR AGREEMENT RELATING TO
THE LOAN.
9.5
Service of Process. Maker hereby consents to process being served in any
suit, action, or proceeding instituted in connection with this Note by delivery of a copy thereof
by certified mail, postage prepaid, return receipt requested, to Maker, and/or by delivery of a
copy thereof to a registered agent of Maker. Refusal to accept delivery, and/or avoidance of
delivery, shall be deemed to constitute delivery. Maker irrevocably agrees that service in
accordance with this Section 9.5 shall be deemed in every respect effective service of process upon
Maker in any such suit, action or proceeding, and shall, to the fullest extent permitted by law, be
taken and held to be valid personal service upon Maker. Nothing in this Section 9.5 shall affect
the right of Holder to serve process in any manner otherwise permitted by law or limit the right of
Holder otherwise to bring proceedings against Maker in the courts of any jurisdiction or
jurisdictions.
SECTION 10. COVENANTS.
10.1
Affirmative Covenants. So long as this Note shall remain outstanding:
(a) Office. Maker shall maintain its head office in the United States.
(b) Use of Proceeds. Maker shall use the proceeds from this Note for operating
expenses and other obligations of the Company incurred in pursuing the Company’s business plan and
strategy including, without limitation, clinical trial expenses, research and development expenses,
expenses related to regulatory filings and processes with the US Food and Drug Administration
(“FDA”) and applicable regulators in various international markets, preparations for commercial
delivery of the Company’s products in various international markets, expenses related to US
Securities and Exchange Commission (“SEC”) filings and processes, expenses related to salaries and
other general and administrative operations, expenses related to litigation, and expenses of
accountants, attorneys, consultants and other professionals.
(c) Seniority. The indebtedness evidenced by this Note: (i) shall be pari passu with
any bridge loan financing provided by Toucan Capital, Cognate BioServices or their assigns
hereafter on substantially the same terms and conditions as this Note, and any other indebtedness
or obligations of Maker to Holder, Toucan Capital and/or Cognate BioServices; (ii) shall be senior
in all respects to all other existing indebtedness or obligations of Maker of any kind, direct or
indirect, contingent or otherwise, other than obligations of Maker owed directly to state or
federal government and other than as provided in this Section 10.1(c)(i).
(d) Regulatory Information. So long as any principal or other obligation under this
Note shall remain outstanding, Maker shall provide to Holder, within the applicable timeframe
specified by Holder, all such information and assessments as may be necessary or desirable in order
for Holder to comply with its reporting obligations to any governmental agency or authority
including, without limitation, the US Small Business Administration (“SBA”). To the extent that
any such information constitutes material non-public information, Holder agrees to keep such
information cmfidential in accordance with applicable securities laws.
(e) Business Activity. So long as any principal or other obligation under this Note
shall remain outstanding, Maker shall make no change in its business activity that would render it
or any of its business activities non-compliant with SBA regulations and guidelines.
10.2
Negative Covenants. So long as any principal or other obligation under
this Note shall remain outstanding:
(a) No Liens. Maker shall not grant to any person or entity a security interest,
lien, license, or other encumbrance of any kind, direct or indirect, contingent or otherwise, in,
to or upon any assets of Maker, including, without limitation, any intellectual property of any
kind (collectively, “Liens”), except (i) Liens to secure further financing for the purpose of (x)
repaying the Principal Amount and any other amounts due pursuant to this Note and any other
notes
under which the repayment of principal and other consideration is pari passu with the repayment
under this Note, or (y) funding the further operations of the Company, or (ii) Liens imposed by law
for taxes that are not yet due or are being contested in good faith by the Company.
(b) No Conflicting Agreements. Maker shall not enter into any agreement that
would materially impair, interfere or conflict with Maker’s obligations hereunder.
(c) No Distributions or Redemptions. Maker shall not declare or pay any dividends or
make any distributions of cash, property or securities of Maker with respect to any shares of its
common stock, preferred stock or any other class or series of its stock, or, directly or indirectly
(except for repurchases of common stock by Maker in accordance with the terms of employee benefit
plans or written agreement between Maker and any of its employees approved by the Board of
Directors of Maker prior to April 29, 2008), redeem, purchase, or otherwise acquire for any
consideration any shares of its common stock or any other class of its stock.
(d) Other Limitations.
(i) Maker shall not change the nature of its business activity in a manner that would cause a
violation of 13 C.F.R. Section 107.720 and/or Section 107.760(b) (including, without limitation, by
undertaking real estate, film production or oil and gas exploration activities).
(ii) Maker will at all times comply with the non-discrimination requirements of 13 C.F.R.
Parts 112, 113 and 117.
(iii) For a period of at least one year after the date of this Note, Maker will locate no more
than 49 percent of the employees or tangible assets of Maker outside the United States.
SECTION 11. STOCK ISSUANCE, STOCK PRICE
11.1 Partial Repayment in Stock. For the issuance of any common stock which Holder
may elect, in its sole discretion, to receive in partial satisfaction of the Company’s obligation
to pay the Repayment Amount on the Maturity Date, as provided in Section 1, the price per share of
such common stock shall be the average of the closing price on the US Nasdaq Over the Counter
Bulletin Board Market on each of the ten (10) trading days preceding the date of execution of this
Note.
11.2 Default Payments. In the event that a Default Payment becomes due from Maker to
Holder as provided in Section 3, the issuance of common stock in satisfaction of such Default
Payments shall be at the price per share equal to the average of the closing price of the Company’s
common stock on the US Nasdaq Over the Counter Bulletin Board Market on each of the ten (10)
trading days preceding (a) the date on which such Default Payment becomes due, or (b) the date on
which such Default Payment is made, whichever is lower.
11.3 Adjustments for Stock Splits, Dividends, Etc. In the event of changes in the Company’s
common stock by reason of stock dividends, splits, recapitalizations, reclassifications,
combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the
number of shares of common stock issuable to the Holder hereunder shall be correspondingly adjusted
to give the Holder, upon such issuance, the total number, class, and kind of shares as the Holder
would have owned had such shares of common stock been issued immediately prior to such changes, and
had the Holder continued to hold such shares until after the changes requiring such adjustment.
SECTION 12. MAKER’S REPRESENTATIONS AND WARRANTIES.
Except as disclosed in the Maker’s public filings with the SEC, Maker represents and warrants the
following:
12.1
Organization, Good Standing and Qualification. Maker is a corporation
duly organized, validly existing and in good standing under the laws of the State of Delaware in
the United States, and has all requisite corporate power and authority to carry on its business.
Maker is duly qualified to transact business and is in good standing in each jurisdiction in which
the failure so to qualify would have a material adverse effect on its business, properties,
operations, prospects or condition (financial or otherwise).
12.2
Authorization. The execution, delivery and performance by Maker of this
Note, and the transactions contemplated hereunder (including, without limitation, the issuance of
common stock), have been duly authorized by all requisite corporate action by Maker in accordance
with Delaware law. This Note is a valid and binding obligation of Maker, enforceable against Maker
in accordance with its terms, except as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, or other laws of general application affecting enforcements of
creditors’ rights or general principles of equity.
12.3
No Conflicts. The execution, delivery, performance, issuance, sale and
delivery of this Note and compliance with the provisions hereof by Maker will not, to the knowledge
of Maker, (a) violate any provision of any law, statute, rule or regulation applicable to Maker or
any order, judgment or decree of any court, arbitrator, administrative agency or other governmental
body applicable to Maker or any of its assets or (b) conflict with or result in any material breach
of any of the terms or conditions of any agreement or instrument to which Maker is a party, or give
rise to any right of termination, cancellation or acceleration under any such agreement or
instrument, or result in the creation of any lien or other encumbrance upon any of the material
assets of Maker.
12.4
Litigation. There is no action, suit, proceeding or investigation
pending or, to the knowledge of Maker, currently threatened against Maker, and/or its directors,
officers, advisers, agents, properties, assets or business, in each case relating to Maker and/or
its business, assets, operations or properties.
12.5
No Liens. The material assets of Maker are not subject to any existing
lien, pledge, security interest or other encumbrance, direct or indirect, contingent or otherwise.
12.6 “Small Business”.
(a) Small Business Status. Maker together with its “affiliates” (as that term is
defined in Section 121.103 of Title 13 of Code of Federal Regulations (the “Federal Regulations”))
is a “small business concern” within the meaning of the Small Business Investment Act of 1958, as
amended (the “Small Business Act” or “SBIA”), and the regulations promulgated thereunder, including
Section 121.301(c) of Title 13, Code of Federal Regulations.
(b) Information for SBA Reports. Maker has delivered and/or will deliver to Holder
certain information, set forth by and regarding the Maker and its affiliates in connection with
this Note, on SBA Forms 480, 652 and Part A and B of Form 1031. This information delivered was
true, accurate, complete and correct in all material respects, and any information yet to be
delivered will be true, accurate, complete and correct in all material respects, and in form and
substance acceptable to Holder.
(c) Eligibility. Maker is eligible for financing by Holder pursuant to Section
107.720 of Title 13 of the Federal Regulations and any other SBA regulations.
SECTION 13. HOLDER’S REPRESENTATIONS AND WARRANTIES
Holder understands that the shares of common stock to be issued to Holder hereunder have not been
and will not be registered within any designated timeframe under the Securities Act of 1933, as
amended (the “Securities Act”). Holder also understands that the common stock is being offered
and sold pursuant to an exemption from registration contained in the Securities Act based in part
upon Holder’s representations contained in this Note. Holder hereby represents and warrants as
follows:
13.1
Investment Experience. Holder has substantial experience in evaluating
and investing in private placement transactions of securities, and is capable of evaluating the
merits and risks of its investment in Maker and has the capacity to protect its own interests.
13.2
Investment Purpose. Holder is acquiring the common stock for its own
account for investment only, and not with a view towards distribution.
13.3
No Solicitation. Holder is not aware of publication of any
advertisement in connection with the issuance of shares of common stock contemplated hereby.
13.4
Accredited Investor. Holder is an “accredited investor” within the
meaning of Regulation D under the Securities Act.
13.5
Access to Information. Holder has had access to publicly available
financial statements and other information regarding Maker and has had an opportunity to discuss
such publicaly available information with authorized representatives of Maker. Holder has also had
the opportunity to ask questions of and receive answers from, Maker and its management regarding
the terms and conditions of the investment contemplated hereby.
13.6
Stock Legend. Holder understands that all certificates evidencing the
common stock issued to Holder hereunder shall bear a legend, prominently stamped or printed
thereon, reading substantially as follows:
“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT
BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT AND APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE ACT.”
SECTION 14. PIGGYBACK REGISTRATION RIGHTS.
14.1
Piggyback Registrations. The Company shall notify the Holder in writing
at least fifteen (15) business days prior to the filing of any registration statement under the
Securities Act for purposes of a public offering of securities of the Company (other than
registration statements relating to employee benefit plans or with respect to corporate
reorganizations or other transactions under Rule 145 of the Securities Act), and shall afford the
Holder an opportunity to include in such registration statement all or part of the shares of common
stock issued pursuant to Section 11 hereof and held at such time by Holder (the “Registrable
Securities”). If Holder desires to include in any such registration statement all or any part of
the Registrable Securities held by it, Holder shall so notify the Company in writing within ten
(10) business days after the above-described notice from the Company. Holder’s notice to the
Company shall state the number of shares of Registrable Securities that Holder wishes to include in
such registration statement.
14.2
Underwriting. If the registration statement under which the Company
gives notice under this Section 14 is for an underwritten offering, the Company shall so advise
Holder. In such event, the right of Holder to include its Registrable Securities in a registration
pursuant to this Section 14 shall be conditioned upon the Holder’s participation in such
underwriting and the inclusion of the Holder’s Registrable Securities in the underwriting to the
extent provided herein. Holder shall enter into an underwriting agreement in customary form with
the underwriter or underwriters selected for such underwriting by the Company. If the underwriter
determines in good faith that marketing factors require a limitation of the number of shares to be
underwritten, the number of shares that may be included in the underwriting shall be allocated,
first, to the Company; second, to all other holders of registration rights in effect as of the date
hereof (the “Pre-existing Rights Holders”) that have elected to exercise such rights in connection
with the registration statement; third, to Holder; and fourth, to any other shareholders of the
Company (other than Holder and the Pre-Existing Rights Holders) on a pro rata basis.
14.4
Expenses Of Registration. All expenses incurred in connection with any
registration, qualification or compliance pursuant to this Section 14 shall be borne by the
Company, “Registration Expenses” including, without limitation, all registration and filing fees,
printing expenses, attorneys’ fees for the Company’s counsel and Holder’s counsel, blue sky fees
and expenses, provided, however, that all discounts and selling commissions applicable to the sale
incurred in connection with any registrations of Registrable Securities hereunder, shall be borne
by the Holder on the basis of the number of shares sold by Holder.
SECTION 15. INDEMNIFICATION
15.1
Indemnification.
(a) In addition to all rights and remedies available to Holder at law or in equity, Maker
shall indemnify Holder and each subsequent holder of this Note, and their respective affiliates,
stockholders, limited partners, general partners, officers, directors, managers, employees, agents,
representatives, successors and assigns (collectively, the “Indemnified Persons”) and pay on behalf
of or reimburse such party for any losses, damages, or expenses, including, without limitation,
reasonable attorneys’ fees and all amounts paid in investigation, defense or settlement of any of
the foregoing which any Indemnified Person may suffer, sustain or become subject to as a result of
or in connection with any material misrepresentation in, or material omission from, any of the
representations and warranties, or any material breach of any covenant or agreement on the part of
Maker under this Note, provided, however, that notwithstanding the foregoing or any other agreement
to the contrary, in no event shall Maker be liable for indirect or consequential losses or damages
of any kind, and in no event shall Maker be liable for any losses or damages resulting from the
gross negligence or willful misconduct of Holder or a subsequent holder of this Note.
(b) Within five (5) business days after receipt of notice of commencement of any action or the
assertion of any claim by a third party, Holder shall give Maker written notice thereof together
with a copy of such claim, process or other legal pleading of such claim. Maker shall have the
right to assist in the defense thereof by representation of its own choosing, at its own expense.
15.2
Survival. All indemnification rights hereunder shall survive the
execution and delivery of this Note and the consummation of the transactions contemplated
hereunder, for a period of two (2) years, regardless of any investigation, inquiry or examination
made for or on behalf of, or any knowledge of Holder and/or any of the Indemnified Persons, or the
acceptance by Holder of any certificate or opinion.
SECTION 16. REPLACEMENT OF NOTE.
Upon receipt by Maker of reasonable evidence of the loss, theft, destruction, or mutilation of
this Note, Maker will deliver a new Note containing the same terms and conditions in lieu of this
Note. Any Note delivered in accordance with the provisions of this Section 6 shall be dated as of
the date of this Note.
SECTION 17. MISCELLANEOUS.
17.1
Notices. All notices, demands and requests of any kind to be delivered
to any party in connection with this Note shall be in writing and shall be deemed to be effective
upon delivery if (i) personally delivered, (ii) sent by confirmed facsimile with a copy sent by
nationally or internationall recognized overnight courier, (iii) sent by nationally or
internationally recognized overnight courier, or (iv) sent by registered or certified mail, return
receipt requested and postage prepaid, addressed as follows:
| if to Maker: | Northwest Biotherapeutics, Inc. | |||
| 0000 Xxxxxxxxx Xxxxxx | ||||
| Xxxxx 000 | ||||
| Xxxxxxxx, XX 00000 | ||||
| Tel: x0-000-000-0000 | ||||
| Fax: x0-000-000-0000 | ||||
| Attention: Xxxxx Xxxxxxx | ||||
| xxxxxxxx@xxxxx.xxx | ||||
| with a copy to: | Xxxxx Xxxxxxx, Esq. | |||
| Xxxxxxxxx & Xxxxxxx | ||||
| 0000 Xxxxxxxxxxxx Xxxxxx, X.X. | ||||
| Xxxxxxxxxx, XX 00000-0000 | ||||
| Tel: x0-000-000-0000 | ||||
| Fax: x0- 000-000-0000 | ||||
| xxxxxxxx@xxx.xxx | ||||
| if to Holder: | Al Rajhi Holdings WLL | |||
| ARH Suisse SA | ||||
| 0 Xxx Xxxxxxx | ||||
| 0000 Xxxxxx | ||||
| Xxxxxx | ||||
| Tel: x00 00 000 00 00 | ||||
| Fax: xxxxxxxxxxx | ||||
| Attention: Xxxxxxx Xxxxxxxx | ||||
| xxxxxxx.xxxxxxxx@rajhi xxxxxxxx.xxx | ||||
| with a copy to: | Xxx X. Xxxx, Esq. | |||
| Xxxxxxxxxxxx Xxxxxxx | ||||
| 00xxx, xxx xxx Xxxxx | ||||
| 0000 Xxxxxx | ||||
| Xxxxxxxxxxx | ||||
| Tel: x00 00 000 0000 | ||||
| Fax: x00 00 000 0000 | ||||
| xxx.xxxx@xxxxxxx.xx |
or to such other address as the party to whom notice is to be given may have furnished to the other
parties hereto in writing in accordance with the provisions of this Section.
17.2
Parties In Interest; Assignment. This Note shall bind and inure to the
benefit of Holder, Maker and their respective successors and permitted assigns. Maker shall not
transfer or assign this Note without the prior written consent of Holder. Holder may transfer and
assign this note without the prior consent of Maker.
17.3
Entire Agreement. This Note contains the entire understanding of the
parties with respect to the subject matter hereof and supersedes all prior agreements and
understandings among the parties with respect thereto.
17.4 Severability. If one or more provisions of this Note are held to be
unenforceable under applicable law, then (i) such provision shall be excluded from this Note, (ii)
the balance of the Note shall be interpreted as if such provision were so excluded, (iii) the
balance of the Note shall be enforceable in accordance with its terms, and (iv) the parties shall
negotiate in good faith to amend or add to the provisions of this Note to effectuate as nearly as
reasonably practicable, and as nearly as permitted under applicable law, the original intent of the
parties with respect to the provision excluded.
17.5
Amendments. No provision of this Note may be amended or waived without
the express written consent of both Maker and Holder, provided, however, that Holder may waive any
provision hereof that inures to the benefit of Holder without the prior written consent of Maker.
17.6
Headings. The section and paragraph headings contained in this Note are
for reference purposes only and shall not affect in any way the meaning or interpretation of this
Note.
17.7
Governing Law. This Note shall be governed by and construed in
accordance with the laws of the U.S. State of New York, other than any rules relating to choice of
law.
17.8
Nature of Obligation. This Note is being made for business and
investment purposes, and not for household or other purposes.
17.9
Expenses. Maker shall pay, reimburse or otherwise satisfy, upon demand
of Holder, all fees, costs and expenses incurred and/or undertaken, and to be incurred and/or
undertaken, by Holder relating to the preparation, development and execution of this Note.
17.10
No Third Party Rights. A person who is not a party to this Note shall
not have any rights under or in connection with it by virtue of the Contracts (Rights of Third
Parties) Xxx 0000. The rights of the parties to terminate, rescind or agree any variation, waiver
or settlement under this Note is not subject to the consent of any person that is not a party to
this Note.
17.11
Counterparts. This Note may be executed and delivered in any number of
counterparts, each of which is an original and which, together, have the same effect as if each
party had signed the same document.
IN WITNESS WHEREOF, Maker has caused this Note to be duly executed by its duly authorized
person(s) as of the date first written above.
| NORTHWEST BIOTHERAPEUTICS, INC. | AL RAJHI HOLDINGS WLL | |||||||
By:
|
/s/Xxxxxxx X.Xxxxxx | By: | /s/Khalid Al Rajhi | |||||
Name:
|
Xxxxxxx X. Xxxxxx | Name: | Khalid Al Rajhi | |||||
Title:
|
Senior Vice President – Chief Financial Officer |
Title: | Chief Executive Officer | |||||
